The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells

The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells

Mantle cell lymphoma (MCL) accounts for 5%–10% of all lymphomas. The disease’s genetic hallmark is the t(11; 14)(q13; q32) translocation. In younger patients, the first-line treatment is chemoimmunotherapy followed by autologous stem cell transplantation. Upon disease progression, novel and targeted...

Full description

Bibliographic Details
Main Authors: Moritz Bewarder, Maximilian Kiefer, Helene Will, Kathrin Olesch, Clara Moelle, Stephan Stilgenbauer, Konstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Joerg Thomas Bittenbring, Natalie Fadle, Evi Regitz, Lea Kaschek, Markus Hoth, Frank Neumann, Klaus-Dieter Preuss, Michael Pfreundschuh, Lorenz Thurner
Format: Article
Language:English
Published: Wolters Kluwer 2021-08-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000620

Internet

http://journals.lww.com/10.1097/HS9.0000000000000620

Similar Items